Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 13/20 | 0.42 |
| ▸ | CBLB | Q13191 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | MYLK | Q15746 | 2/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL945065 | 0.82 | MAP3K5 (0.61) | MAP3K5CBLBMYLK | |
| SCHEMBL945258 | 0.73 | MAP3K5 (0.61) | MAP3K5CBLBMYLK | |
| SCHEMBL943672 | 0.72 | MAP3K5 (0.51) | MAP3K5TNF | |
| SCHEMBL22739076 | 0.72 | MAP3K5 (0.40) | MAP3K5CBLBTNFAKT1 | |
| SCHEMBL946060 | 0.71 | MAP3K5 (0.52) | MAP3K5TNF | |
| SCHEMBL945462 | 0.71 | MAP3K5 (0.59) | MAP3K5CBLB | |
| SCHEMBL945552 | 0.71 | MAP3K5 (0.63) | MAP3K5CBLBTNFMYLK | |
| SCHEMBL946466 | 0.71 | MAP3K5 (0.51) | MAP3K5CBLBTNFMYLK | |
| SCHEMBL16848415 | 0.71 | MAP3K5 (0.65) | MAP3K5CBLB | |
| SCHEMBL943565 | 0.70 | MAP3K5 (0.60) | MAP3K5CBLBMGLLMYLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3363797-B1 | ORAL DOSAGE FORM OF APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2020-12-02 | — | — | EP | disclosed |